Maintenance treatment with antipsychotic drugs for schizophrenia.

@article{Leucht2012MaintenanceTW,
  title={Maintenance treatment with antipsychotic drugs for schizophrenia.},
  author={Stefan Leucht and Magdolna Tardy and Katja Komossa and Stephan Heres and Werner Kissling and John M. Davis},
  journal={The Cochrane database of systematic reviews},
  year={2012},
  volume={5},
  pages={
          CD008016
        }
}
BACKGROUND The symptoms and signs of schizophrenia have been firmly linked to high levels of dopamine in specific areas of the brain (limbic system. [] Key MethodSEARCH METHODS We searched the Cochrane Schizophrenia Group's Specialised Register (November 2008), with additional searches of MEDLINE, EMBASE and clinicaltrials.gov (June 2011).

Figures from this paper

Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.
TLDR
The findings of this meta-analysis suggest that doses higher than approximately 5-mg/d risperidone equivalent may provide limited additional benefit for relapse prevention but more adverse events.
Maintenance treatment with antipsychotic drugs for schizophrenia.
TLDR
The efficacy of antipsychotic drugs for maintenance treatment in schizophrenia was clear and hospitalisation was reduced and underpowered data revealed no evidence of a difference between groups for the outcome 'Death due to suicide'.
Haloperidol discontinuation for people with schizophrenia.
TLDR
Very low quality evidence shows that discontinuation of haloperidol is associated with an increased risk of relapse and a reduction in the risk of 'global state improvement'.
Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
TLDR
Except for apparent superiority of olanzapine and fluphenazine decanoate over chlorpromazine, most agents showed intermediate efficacy for relapse prevention and differences among them were minor.
Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance.
TLDR
Significant differences between individual antipsychotics and increased variability in side effects in patients under treatment with antipsychotic drugs are found suggesting that subgroups of patients or individual patients may benefit from treatment allocation through stratified or personalized medicine.
Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective
  • S. Lawrie
  • Psychology, Medicine
    Therapeutic advances in psychopharmacology
  • 2018
TLDR
The case against antipsychotics is not proven and the jury is out on any significance of putative antipsychotic-induced brain changes, as the balance of probabilities is that antippsychotic drugs do not cause adverse structural brain changes in schizophrenia.
A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina
TLDR
It is shown that intermittent treatment usually fails to prevent relapses due to irregular protection, therefore continuous treatment is more effective, and LAIR exhibits superior cost effectiveness compared with haloperidol depot.
Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations.
TLDR
This review investigated the hypothesized normalization of the functional magnetic resonance imaging (fMRI) blood oxygen level dependent signal in the context of antipsychotic treatment and provided several neuronal-based interpretations of changes of the BOLD signal that may be attributable to long-term antipsychotics administration.
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders.
TLDR
Even when the confound by indication for prescribing antipsychotic medication is controlled for, participants with schizophrenia and affective psychosis do better than their medicated cohorts, strongly confirming the importance of exposing the role of aiDSP and antipsychotics drug resistance.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 322 REFERENCES
Cessation of medication for people with schizophrenia already stable on chlorpromazine.
TLDR
This review confirms clinical experience and quantifies the risks of stopping chlorpromazine medication for a group of people with schizophrenia who are stable on this drug.
Olanzapine for schizophrenia.
TLDR
There is little to choose between the atypical antipsychotic drugs, although olanzapine may cause fewer extrapyramidal adverse effects than other drugs in this category, and results between three to 12 months suggest a clinically important average gain of four kilograms for people given olanZapine.
Quetiapine for schizophrenia.
TLDR
Quetiapine is as potent as chlorpromazine and haloperidol as regards global and mental state but it may cause higher incidences of dry mouth and sleepiness and side effects such as dizziness and dry mouth are more prevalent in the quetiAPine treated group.
Clonidine treatment of schizophrenia
TLDR
Preliminary evidence that clonidine may be an effective alternative to neuroleptics is provided, particularly for patients for whom the dopaminergic blocking action of the neuroleptic drugs is undesirable.
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
TLDR
Overall, the currently available data suggest that new-generation antipsychotic drugs have the potential to reduce relapse rates.
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
TLDR
Zotepine is effective in preventing recurrence in patients with chronic schizophrenia, and scores on the BPRS and CGI supported the efficacy of zotEPine.
...
1
2
3
4
5
...